MCID: NRL004
MIFTS: 52

Neuroleptic Malignant Syndrome malady

Rare diseases, Neuronal diseases categories

Aliases & Classifications for Neuroleptic Malignant Syndrome

About this section
Sources:
9Disease Ontology, 41NIH Rare Diseases, 42NINDS, 11DISEASES, 43Novoseek, 47Orphanet, 60UMLS, 27ICD9CM, 55SNOMED-CT, 33MeSH, 34MESH via Orphanet, 26ICD10 via Orphanet, 61UMLS via Orphanet
See all sources

Neuroleptic Malignant Syndrome, Aliases & Descriptions:

Name: Neuroleptic Malignant Syndrome 9 41 42 11 43 47 60


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases
Anatomical: Neuronal diseases


Characteristics (Orphanet epidemiological data):

47
neuroleptic malignant syndrome:
Prevalence: 1-5/10000 (Europe)


External Ids:

Disease Ontology9 DOID:14464
ICD9CM27 333.92
MeSH33 D009459
Orphanet47 94093
MESH via Orphanet34 D009459
ICD10 via Orphanet26 G21.0
UMLS via Orphanet61 C0027849

Summaries for Neuroleptic Malignant Syndrome

About this section


NINDS:42 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

MalaCards based summary: Neuroleptic Malignant Syndrome is related to serotonin syndrome and schizophrenia. An important gene associated with Neuroleptic Malignant Syndrome is NHLRC1 (NHL repeat containing E3 ubiquitin protein ligase 1), and among its related pathways are Monoamine GPCRs and SIDS Susceptibility Pathways. The drugs bromocriptine and dantrolene and the compounds amperozide and mcpp have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and breast, and related mouse phenotypes are cardiovascular system and nervous system.

Wikipedia:63 Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder most often caused by an... more...

Related Diseases for Neuroleptic Malignant Syndrome

About this section

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 159)
idRelated DiseaseScoreTop Affiliating Genes
1serotonin syndrome31.4HTR1A, HTR3A, HTR2A
2schizophrenia31.1DRD2, HTR2A, CYP2D6
3anxiety disorder31.0HTR3A
4cocaine abuse31.0HTR3A, DRD2
5malignant hyperthermia30.9PIK3C2A, MB, RYR1, RYR3
6amnestic disorder30.8HTR1A, HTR3A
7neuropathy30.6RYR1, MB, PIK3C2A
8dementia30.6PIK3C2A, CYP2D6, NHLRC1, HTR2A, HTR3A, HTR1A
9bipolar disorder30.6HTR2A, HTR3A, HTR1A, DRD2
10generalized anxiety disorder30.5HTR2A, HTR3A, HTR1A
11brain disease30.3GPT, CPT2, RYR1
12myocardial infarction29.8PIK3C2A, CHKA, CHKB, HTR2A, HTR3A, MB
13acute myocardial infarction29.5PIK3C2A, CHKA, CHKB, HTR2A, HTR3A, MB
14gas gangrene10.5PIK3C2A
15cardiac rupture10.5CHKB
16cerebritis10.5
17encephalitis10.5
18premature ejaculation10.5HTR1A
19pathological gambling10.5DRD2
20carnitine palmitoyltransferase ii deficiency10.5CPT2
21status asthmaticus10.5PIK3C2A
22pericardial effusion10.5PIK3C2A, CHKB
23alexithymia10.5ANKK1
24brain injury10.4
25central core myopathy10.4RYR3
26intermediate coronary syndrome10.4PIK3C2A, MB
27ectopic pregnancy10.4PIK3C2A, CHKB
28hypokalemic periodic paralysis, type 110.4RYR1
29mcardle disease10.4CHKB, CPT2
30heroin dependence10.4ANKK1, DRD2
31cerebral palsy10.4
32traumatic brain injury10.4
33cerebellar degeneration10.4
34motion sickness10.4HTR3A, HTR1A
35creatine phosphokinase, elevated serum10.4PIK3C2A, CHKB, MB
36restless legs syndrome10.4HTR3A, DRD2
37major depressive disorder and accelerated response to antidepressant drug treatment10.4HTR2A, HTR1A
38spinocerebellar ataxia10.4CHKB, MB
39coronary artery vasospasm10.4CHKB, HTR2A
40metabolic acidosis10.4PIK3C2A, CHKB, MB
41duchenne muscular dystrophy10.4MB, CHKB, PIK3C2A
42compartment syndrome10.3CHKA, CHKB, MB
43social phobia10.3HTR3A, HTR1A, DRD2
44parkinson disease, late-onset10.3CYP2D6, HTR1A, DRD2
45systemic lupus erythematosus10.3
46burns10.3
47diabetic ketoacidosis10.3
48status epilepticus10.3
49striatonigral degeneration10.3
50dystonia10.3

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to neuroleptic malignant syndrome

Symptoms for Neuroleptic Malignant Syndrome

About this section

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

About this section

Drug clinical trials:

Search ClinicalTrials for Neuroleptic Malignant Syndrome

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS60/NDF-RT39:

Genetic Tests for Neuroleptic Malignant Syndrome

About this section

Anatomical Context for Neuroleptic Malignant Syndrome

About this section

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

31
Brain, Liver, Breast, Subthalamic nucleus, Tongue

Animal Models for Neuroleptic Malignant Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053857.9F2RL1, POMC, HTR1A, DRD2, MB, NPPB
2MP:00036317.8F2RL1, NHLRC1, POMC, CHKB, HTR3A, HTR1A
3MP:00053697.5RYR3, NHLRC1, CHKB, HTR2A, HTR3A, DRD2
4MP:00053867.3F2RL1, NHLRC1, POMC, CHKB, HTR2A, HTR3A
5MP:00107687.0PIK3C2A, POMC, CHKA, HTR3A, HTR1A, DRD2
6MP:00053766.6POMC, NHLRC1, PIK3C2A, F2RL1, CHKA, CHKB

Publications for Neuroleptic Malignant Syndrome

About this section

Articles related to Neuroleptic Malignant Syndrome:

(show top 50)    (show all 563)
idTitleAuthorsYear
1
Recurrence of neuroleptic malignant syndrome. (24096397)
2013
2
Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report. (23288234)
2013
3
Neuroleptic malignant syndrome masked by cerebral malaria. (23704432)
2013
4
Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity. (22953147)
2012
5
Comment: Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. (22414792)
2012
6
Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. (21601731)
2011
7
An unusual case of neuroleptic malignant syndrome. (20160232)
2010
8
Neuroleptic malignant syndrome following levomepromazine discontinuation. (20463130)
2010
9
Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine. (20080143)
2010
10
An unrecognised case of withdrawal neuroleptic malignant syndrome: a case report. (20025106)
2009
11
Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. (19067992)
2009
12
Neuroleptic malignant syndrome secondary to quetiapine. (19299325)
2009
13
Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. (19191213)
2009
14
Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. (19673089)
2009
15
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. (18572981)
2008
16
A case of 45,XO/47,XYY mosaicism with psychotic symptoms and neuroleptic malignant syndrome. (17478025)
2007
17
Late-onset neuroleptic malignant syndrome in a patient using olanzapine. (17502780)
2007
18
Hypophosphatemia and neuroleptic malignant syndrome. (17502779)
2007
19
Neuroleptic malignant syndrome and serotonin syndrome. (17645916)
2007
20
Neuroleptic malignant syndrome in elderly patients. (17425496)
2007
21
Possible neuroleptic malignant syndrome associated with paliperidone. (18070861)
2007
22
Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. (17607339)
2007
23
Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. (17453880)
2007
24
Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient. (16618352)
2006
25
Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. (17119106)
2006
26
Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child. (17156702)
2006
27
Neuroleptic malignant syndrome: a review and report of six cases. (17214072)
2006
28
A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. (17017330)
2006
29
The WHO analgesic ladder and neuroleptic malignant syndrome. (17067339)
2006
30
Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome. (16669738)
2006
31
Neuroleptic malignant syndrome after an emergency operation for acute appendicitis perforation. (15646452)
2004
32
Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. (15266995)
2004
33
Neuroleptic malignant syndrome and atypical antipsychotic drugs. (15119907)
2004
34
Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. (12605103)
2003
35
Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene. (12965323)
2003
36
Risk factors in neuroleptic malignant syndrome. A case-control study. (12558541)
2003
37
Neuroleptic malignant syndrome and low-dose olanzapine. (12668376)
2003
38
Neuroleptic malignant syndrome: uncommon postoperative diagnostic dilemma. (12538292)
2002
39
Persistent fever in a case of typhoid--an unusual cause of neuroleptic malignant syndrome. (11225156)
2001
40
Three patients with isolated adrenocorticotropin deficiency presenting with neuroleptic malignant syndrome-like symptoms. (11446676)
2001
41
Neuroleptic malignant syndrome in pregnancy. (11704197)
2001
42
Neuroleptic malignant syndrome after venlafaxine. (10675082)
2000
43
Neuroleptic malignant syndrome: a diagnosis easily missed. (11072926)
2000
44
CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. (9892857)
1999
45
Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. (10378156)
1999
46
"Multiple ECT" for neuroleptic malignant syndrome. (10614039)
1999
47
Clozapine-induced neuroleptic malignant syndrome: an interaction between dopaminergic and purinergic systems? (10512095)
1999
48
Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. (8777769)
1996
49
The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. (8101383)
1993
50
Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. (2647908)
1989

Variations for Neuroleptic Malignant Syndrome

About this section

Expression for genes affiliated with Neuroleptic Malignant Syndrome

About this section
Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for genes affiliated with Neuroleptic Malignant Syndrome

About this section

Pathways related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.6HTR2A, HTR1A, DRD2
29.6HTR2A, HTR3A, HTR1A
39.6HTR2A, HTR3A, HTR1A
4
Show member pathways
9.2RYR3, RYR1, HTR3A
5
Show member pathways
8.9F2RL1, POMC, HTR2A, HTR1A, DRD2
6
Show member pathways
8.9CHKB, CHKA, PIK3C2A
7
Show member pathways
8.6RYR3, RYR1, HTR1A, HTR3A, HTR2A
8
Show member pathways
8.1RYR3, RYR1, DRD2, HTR1A, HTR3A, HTR2A
9
Show member pathways
7.3PIK3C2A, CYP2D6, NHLRC1, GPT, CPT2, POMC

Compounds for genes affiliated with Neuroleptic Malignant Syndrome

About this section

Compounds related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 338)
idCompoundScoreTop Affiliating Genes
1amperozide439.7HTR3A, DRD2, HTR2A, HTR1A
2mcpp439.7HTR1A, CYP2D6, HTR2A, HTR3A
3piperazine43 1210.7DRD2, HTR1A, CYP2D6, HTR2A
4granisetron49 43 1211.7HTR2A, CYP2D6, DRD2, HTR3A
5pindolol43 28 1211.7HTR1A, HTR2A, HTR3A, CYP2D6
6trimipramine43 49 1211.6HTR2A, HTR1A, CYP2D6, DRD2
7spiperone43 2810.6DRD2, HTR1A, HTR3A, HTR2A
8sertindole28 43 1211.6DRD2, HTR1A, HTR2A, CYP2D6
9antipsychotics499.6ANKK1, HTR2A, DRD2, CYP2D6
10ritanserin43 2810.6HTR1A, DRD2, HTR3A, HTR2A
11buspirone43 28 1211.5HTR2A, HTR1A, HTR3A, DRD2, CYP2D6
12ipsapirone43 2810.5HTR3A, POMC, HTR2A, HTR1A
13iloperidone49 43 28 1212.5HTR2A, CYP2D6, HTR3A, DRD2, HTR1A
14aripiprazole28 43 49 24 1213.5HTR3A, HTR1A, DRD2, HTR2A, CYP2D6
15ziprasidone28 49 43 1212.5DRD2, HTR2A, CYP2D6, HTR1A, HTR3A
16yohimbine43 2 28 1212.5HTR2A, CYP2D6, DRD2, HTR1A, HTR3A
17quetiapine43 49 28 24 1213.5CYP2D6, HTR2A, DRD2, HTR1A, HTR3A
18pimozide28 43 49 1212.4HTR1A, HTR2A, CYP2D6, DRD2
19lisuride43 28 1211.4DRD2, HTR2A, CYP2D6, HTR1A
20fluoxetine43 49 28 1212.4CYP2D6, HTR2A, HTR3A, HTR1A, DRD2
21nefazodone43 49 1211.4CYP2D6, HTR2A, HTR3A, HTR1A
22fenfluramine43 28 1211.3HTR1A, HTR2A, POMC, CYP2D6, HTR3A
23ropinirole43 1210.3CYP2D6, HTR2A, HTR1A, DRD2
24chlorpromazine28 43 49 1212.3CHKB, DRD2, HTR2A, HTR3A, HTR1A, CYP2D6
25alpha-hydroxybutyrate439.1CHKB, GPT, PIK3C2A, MB
26succinylcholine43 49 28 1212.1RYR1, MB, PIK3C2A, CHKB
27olanzapine43 49 28 24 1213.0DRD2, HTR2A, CYP2D6, CHKB, HTR1A, HTR3A
28halothane43 49 28 1211.9CYP2D6, RYR1, CHKB, MB, PIK3C2A
29maoa438.9POMC, HTR2A, HTR1A, DRD2
305-hydroxytryptamine438.9HTR2A, HTR3A, HTR1A, DRD2, F2RL1, POMC
31bromocriptine43 28 1210.7POMC, PIK3C2A, HTR2A, HTR1A, DRD2
32dantrolene28 43 1210.6PIK3C2A, RYR3, RYR1, CHKB, MB
33fluvastatin43 49 28 1211.6PIK3C2A, CYP2D6, GPT, MB, CHKB
34risperidone43 49 28 59 24 1213.6CYP2D6, HTR1A, HTR3A, GPT, CHKB, ANKK1
35citrate438.3PIK3C2A, MB, CPT2, POMC, CHKA, CHKB
36cocaine43 129.3CYP2D6, GPT, MB, POMC, DRD2, PIK3C2A
37prednisolone43 28 1210.2NPPB, MB, CHKB, POMC, GPT, PIK3C2A
38pravastatin43 49 28 24 1212.1PIK3C2A, CYP2D6, CHKB, NPPB, GPT, CHKA
39atorvastatin43 49 28 24 1212.1GPT, CYP2D6, CHKA, CHKB, NPPB, PIK3C2A
40adenylate437.9DRD2, POMC, CHKA, CHKB, HTR3A, HTR1A
41clozapine43 28 49 1210.9ANKK1, DRD2, HTR1A, HTR3A, HTR2A, CHKB
42dopamine43 28 24 1210.8DRD2, NPPB, F2RL1, CYP2D6, POMC, CHKB
43thyroxine43 248.7POMC, CHKA, GPT, CHKB, MB, NPPB
44glycogen43 248.7PIK3C2A, NHLRC1, CHKB, NPPB, GPT, CPT2
45glutamate437.4CHKA, F2RL1, RYR1, MB, DRD2, CHKB
46haloperidol43 49 28 2 1211.1HTR3A, NPPB, MB, DRD2, HTR1A, HTR2A
47creatinine437.1CHKA, POMC, CHKB, MB, NPPB, RYR1
48norepinephrine43 24 128.9HTR3A, HTR2A, CHKB, POMC, F2RL1, HTR1A
49acetylcholine43 49 28 24 1210.7HTR1A, HTR3A, CHKA, POMC, CYP2D6, PIK3C2A
50glucose436.7POMC, F2RL1, PIK3C2A, GPT, CPT2, RYR1

GO Terms for genes affiliated with Neuroleptic Malignant Syndrome

About this section

Cellular components related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:00304249.5DRD2, HTR3A, HTR2A
2junctional membrane complexGO:00303149.4RYR3, RYR1
3integral component of plasma membraneGO:00058878.4F2RL1, HTR2A, HTR3A, HTR1A, DRD2, RYR1

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1regulation of hormone secretionGO:004688310.2HTR1A, HTR2A
2negative regulation of synaptic transmission, glutamatergicGO:005196710.1DRD2, HTR2A
3regulation of behaviorGO:005079510.1HTR1A, HTR2A
4behavioral response to cocaineGO:004814810.1DRD2, HTR2A
5CDP-choline pathwayGO:000665710.0CHKA, CHKB
6temperature homeostasisGO:00016599.9HTR2A, DRD2
7positive regulation of urine volumeGO:00358109.9DRD2, NPPB
8phosphatidylethanolamine biosynthetic processGO:00066469.9CHKB, CHKA
9negative regulation of cytosolic calcium ion concentrationGO:00514819.9RYR3, DRD2
10serotonin receptor signaling pathwayGO:00072109.9HTR1A, HTR3A, HTR2A
11release of sequestered calcium ion into cytosolGO:00512099.8HTR2A, DRD2, RYR1
12positive regulation of renal sodium excretionGO:00358159.8NPPB, DRD2
13cellular response to caffeineGO:00713139.8RYR1, RYR3
14positive regulation of ERK1 and ERK2 cascadeGO:00703749.8F2RL1, HTR2A, DRD2
15phosphatidylcholine biosynthetic processGO:00066569.7CHKB, CHKA
16response to hypoxiaGO:00016669.6RYR1, MB, DRD2
17response to cocaineGO:00422209.6DRD2, HTR3A
18phospholipid metabolic processGO:00066448.8PIK3C2A, CHKA, CHKB
19small molecule metabolic processGO:00442818.1PIK3C2A, CYP2D6, NHLRC1, GPT, CPT2, CHKA

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1choline kinase activityGO:00041039.8CHKB, CHKA
2G-protein alpha-subunit bindingGO:00019659.8HTR2A, F2RL1
3ethanolamine kinase activityGO:00043059.8CHKA, CHKB
4serotonin receptor activityGO:00049939.7HTR2A, HTR3A, HTR1A
5ryanodine-sensitive calcium-release channel activityGO:00052199.5RYR3, RYR1
6serotonin bindingGO:00513789.5HTR3A, HTR2A
7calcium-release channel activityGO:00152789.4RYR3, RYR1
8drug bindingGO:00081449.3DRD2, HTR2A, CHKA, CYP2D6

Products for genes affiliated with Neuroleptic Malignant Syndrome

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Neuroleptic Malignant Syndrome

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet